Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is clearly the lowest from the spectrum of B-cell tumors. In this review, we discuss the antigenic targets exploited in CLL CAR-T therapy, the determinants of favorable responses, as well as the mechanisms of treatment failure specific to this disease.

Central European Institute of Technology Masaryk University 62500 Brno Czech Republic

Zobrazit více v PubMed

Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Döhner H., Hillmen P., Keating M., Montserrat E., Chiorazzi N., et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–2760. doi: 10.1182/blood-2017-09-806398. PubMed DOI

Eichhorst B., Robak T., Montserrat E., Ghia P., Hillmen P., Hallek M., Buske C. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015;26:v78–v84. doi: 10.1093/annonc/mdv303. PubMed DOI

Dreger P., Schetelig J., Andersen N.S., Corradini P., Van Gelder M., Gribben J.G., Kimby E., Michallet M., Moreno C., Stilgenbauer S., et al. Managing high-risk CLL during transition to a new treatment era: Stem cell transplantation or novel agents? Blood. 2014;124:3841–3849. doi: 10.1182/blood-2014-07-586826. PubMed DOI PMC

Dreger P., Ghia P., Schetelig J., Van Gelder M., Kimby E., Michallet M., Moreno C., Robak T., Stilgenbauer S., Montserrat E. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies. Blood. 2018;132:892–902. doi: 10.1182/blood-2018-01-826008. PubMed DOI

Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia. N. Engl. J. Med. 2011;365:725–733. doi: 10.1056/NEJMoa1103849. PubMed DOI PMC

Bechman N., Maher J. Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy—What are we doing; where are we going? Expert Opin. Biol. Ther. 2021;21:627–637. doi: 10.1080/14712598.2021.1857361. PubMed DOI

Eshhar Z., Waks T., Bendavid A., Schindler D.G. Functional expression of chimeric receptor genes in human T cells. J. Immunol. Methods. 2001;248:67–76. doi: 10.1016/S0022-1759(00)00343-4. PubMed DOI

Brocker T., Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J. Exp. Med. 1995;181:1653–1659. doi: 10.1084/jem.181.5.1653. PubMed DOI PMC

Milone M.C., Fish J.D., Carpenito C., Carroll R.G., Binder G.K., Teachey D., Samanta M., Lakhal M., Gloss B., Danet-Desnoyers G., et al. Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. Mol. Ther. 2009;17:1453–1464. doi: 10.1038/mt.2009.83. PubMed DOI PMC

Brentjens R.J., Curran K.J. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematol. Am. Soc. Hematol. Educ. Program. 2012;2012:143–151. doi: 10.1182/asheducation.V2012.1.143.3798224. PubMed DOI PMC

Maude S.L., Laetsch T.W., Buechner J., Rives S., Boyer M., Bittencourt H., Bader P., Verneris M.R., Stefanski H.E., Myers G.D., et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 2018;378:439–448. doi: 10.1056/NEJMoa1709866. PubMed DOI PMC

Locke F.L., Ghobadi A., Jacobson C.A., Miklos D.B., Lekakis L.J., Oluwole O., Lin Y., Braunschweig I., Hill B.T., Timmerman J.M., et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20:31–42. doi: 10.1016/S1470-2045(18)30864-7. PubMed DOI PMC

Fraietta J.A., Lacey S.F., Orlando E.J., Pruteanu-Malinici I., Gohil M., Lundh S., Boesteanu A.C., Wang Y., O’Connor R.S., Hwang W.-T., et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 2018;24:563–571. doi: 10.1038/s41591-018-0010-1. PubMed DOI PMC

Wieczorek A., Uharek L. Genetically modified T cells for the treatment of malignant disease. Transfus. Med. Hemother. 2013;40:388–402. doi: 10.1159/000357163. PubMed DOI PMC

Hulkkonen J., Vilpo L., Hurme M., Vilpo J. Surface antigen expression in chronic lymphocytic leukemia: Clustering analysis, interrelationships and effects of chromosomal abnormalities. Leukemia. 2002;16:178–185. doi: 10.1038/sj.leu.2402363. PubMed DOI

Witzig T.E., Li C.-Y., Tefferi A., Katzmann J.A. Measurement of the Intensity of Cell Surface Antigen Expression in B-Cell Chronic Lymphocytic Leukemia. Am. J. Clin. Pathol. 1994;101:312–317. doi: 10.1093/ajcp/101.3.312. PubMed DOI

Brentjens R.J., Rivière I., Park J.H., Davila M.L., Wang X., Stefanski J., Taylor C., Yeh R., Bartido S., Borquez-Ojeda O., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817–4828. doi: 10.1182/blood-2011-04-348540. PubMed DOI PMC

Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., June C.H. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Sci. Transl. Med. 2011;3:95ra73. doi: 10.1126/scitranslmed.3002842. PubMed DOI PMC

Kochenderfer J.N., Dudley M.E., Feldman S.A., Wilson W.H., Spaner D.E., Maric I., Stetler-Stevenson M., Phan G.Q., Hughes M.S., Sherry R.M., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells. Blood. 2012;119:2709–2720. doi: 10.1182/blood-2011-10-384388. PubMed DOI PMC

Cruz C.R.Y., Micklethwaite K.P., Savoldo B., Ramos C.A., Lam S., Ku S., Diouf O., Liu E., Barrett A.J., Ito S., et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study. Blood. 2013;122:2965–2973. doi: 10.1182/blood-2013-06-506741. PubMed DOI PMC

Kochenderfer J.N., Dudley M.E., Kassim S.H., Somerville R.P., Carpenter R.O., Stetler-Stevenson M., Yang J.C., Phan G.Q., Hughes M.S., Sherry R.M., et al. Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated with Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor. J. Clin. Oncol. 2015;33:540–549. doi: 10.1200/JCO.2014.56.2025. PubMed DOI PMC

Porter D.L., Hwang W.-T., Frey N.V., Lacey S.F., Shaw P.A., Loren A.W., Bagg A., Marcucci K.T., Shen A., Gonzalez V., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 2015;7:303ra139. doi: 10.1126/scitranslmed.aac5415. PubMed DOI PMC

Brudno J.N., Somerville R.P., Shi V., Rose J.J., Halverson D.C., Fowler D.H., Gea-Banacloche J.C., Pavletic S.Z., Hickstein D.D., Lu T.L., et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J. Clin. Oncol. 2016;34:1112–1121. doi: 10.1200/JCO.2015.64.5929. PubMed DOI PMC

Turtle C.J., Hay K.A., Hanafi L.-A., Li D., Cherian S., Chen X., Wood B., Lozanski A., Byrd J.C., Heimfeld S., et al. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated with CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib. J. Clin. Oncol. 2017;35:3010–3020. doi: 10.1200/JCO.2017.72.8519. PubMed DOI PMC

Geyer M., Rivière I., Sénéchal B., Wang X., Wang Y., Purdon T.J., Hsu M., Devlin S.M., Halton E., Lamanna N., et al. Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. Mol. Ther. 2018;26:1896–1905. doi: 10.1016/j.ymthe.2018.05.018. PubMed DOI PMC

Gill M.S.I., Vides B.V., Frey N.V., Metzger B.S., O’Brien M., Hexner E., Mato M.A.R., Lacey B.S.F., Melenhorst J.J., Pequignot M.E., et al. Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate. Blood. 2018;132:298. doi: 10.1182/blood-2018-99-115418. DOI

Siddiqi T., Soumerai J.D., Wierda W.G., Dubovsky J.A., Gillenwater H.H., Gong L., Mitchell M.A., Thorpe B.J., Yang L., Dorritie K.A. Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib. Blood. 2018;132:300. doi: 10.1182/blood-2018-99-110462. DOI

Gauthier J., Hirayama A.V., Purushe J., Hay K.A., Lymp J., Li D.H., Yeung C.C.S., Sheih A., Pender B.S., Hawkins R.M., et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135:1650–1660. doi: 10.1182/blood.2019002936. PubMed DOI PMC

Liu E., Marin D., Banerjee P., Macapinlac H.A., Thompson P., Basar R., Kerbauy L.N., Overman B., Thall P., Kaplan M., et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N. Engl. J. Med. 2020;382:545–553. doi: 10.1056/NEJMoa1910607. PubMed DOI PMC

Frey N.V., Gill S., Hexner E.O., Schuster S., Nasta S., Loren A., Svoboda J., Stadtmauer E., Landsburg D.J., Mato A., et al. Long-Term Outcomes from a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. J. Clin. Oncol. 2020;38:2862–2871. doi: 10.1200/JCO.19.03237. PubMed DOI PMC

Shah N.N., Johnson B.D., Schneider D., Zhu F., Szabo A., Keever-Taylor C.A., Krueger W., Worden A.A., Kadan M.J., Yim S., et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial. Nat. Med. 2020;26:1569–1575. doi: 10.1038/s41591-020-1081-3. PubMed DOI

Ramos C.A., Savoldo B., Torrano V., Ballard B., Zhang H., Dakhova O., Liu E., Carrum G., Kamble R.T., Gee A.P., et al. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J. Clin. Investig. 2016;126:2588–2596. doi: 10.1172/JCI86000. PubMed DOI PMC

Sato S., Jansen P.J., Tedder T.F. CD19 and CD22 expression reciprocally regulates tyrosine phosphorylation of Vav protein during B lymphocyte signaling. Proc. Natl. Acad. Sci. USA. 1997;94:13158–13162. doi: 10.1073/pnas.94.24.13158. PubMed DOI PMC

Scheuermann R.H., Racila E. CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy. Leuk. Lymphoma. 1995;18:385–397. doi: 10.3109/10428199509059636. PubMed DOI

Uckun F., Jaszcz W., Ambrus J., Fauci A., Gajl-Peczalska K., Song C., Wick M.R., Myers D., Waddick K., Ledbetter J. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood. 1988;71:13–29. doi: 10.1182/blood.V71.1.13.13. PubMed DOI

Fraietta J.A., Beckwith K.A., Patel P.R., Ruella M., Zheng Z., Barrett D.M., Lacey S.F., Melenhorst J.J., Mcgettigan S.E., Cook D.R., et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127:1117–1127. doi: 10.1182/blood-2015-11-679134. PubMed DOI PMC

Cappell K.M., Sherry R.M., Yang J.C., Goff S.L., Vanasse D.A., McIntyre L., Rosenberg S.A., Kochenderfer J.N. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. J. Clin. Oncol. 2020;38:3805–3815. doi: 10.1200/JCO.20.01467. PubMed DOI PMC

Park J.H., Rivière I., Gonen M., Wang X., Sénéchal B., Curran K.J., Sauter C., Wang Y., Santomasso B., Mead E., et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N. Engl. J. Med. 2018;378:449–459. doi: 10.1056/NEJMoa1709919. PubMed DOI PMC

Schuster S.J., Svoboda J., Chong E.A., Nasta S.D., Mato A.R., Anak Ö., Brogdon J.L., Pruteanu-Malinici I., Bhoj V., Landsburg D., et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N. Engl. J. Med. 2017;377:2545–2554. doi: 10.1056/NEJMoa1708566. PubMed DOI PMC

Schuster S.J., Bishop M.R., Tam C.S., Waller E.K., Borchmann P., McGuirk J.P., Jäger U., Jaglowski S., Andreadis C., Westin J.R., et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2019;380:45–56. doi: 10.1056/NEJMoa1804980. PubMed DOI

Kozlova V., Ledererova A., Ladungova A., Peschelova H., Janovska P., Slusarczyk A., Domagala J., Kopcil P., Vakulova V., Oppelt J., et al. CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells. PLoS ONE. 2020;15:e0229170. doi: 10.1371/journal.pone.0229170. PubMed DOI PMC

Huhn D. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98:1326–1331. doi: 10.1182/blood.V98.5.1326. PubMed DOI

Hiraga J., Tomita A., Sugimoto T., Shimada K., Ito M., Nakamura S., Kiyoi H., Kinoshita T., Naoe T. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: Its prevalence and clinical significance. Blood. 2009;113:4885–4893. doi: 10.1182/blood-2008-08-175208. PubMed DOI

Zhang W.-Y., Wang Y., Guo Y.-L., Dai H.-R., Yang Q.-M., Zhang Y.-J., Zhang Y., Chen M.-X., Wang C.-M., Feng K.-C., et al. Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An early phase IIa trial report. Signal Transduct. Target. Ther. 2016;1:16002. doi: 10.1038/sigtrans.2016.2. PubMed DOI PMC

Till B.G., Jensen M.C., Wang J., Qian X., Gopal A.K., Maloney D.G., Lindgren C.G., Lin Y., Pagel J.M., Budde L.E., et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: Pilot clinical trial results. Blood. 2012;119:3940–3950. doi: 10.1182/blood-2011-10-387969. PubMed DOI PMC

Vera J., Savoldo B., Vigouroux S., Biagi E., Pule M., Rossig C., Wu J., Heslop H.E., Rooney C.M., Brenner M.K., et al. T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006;108:3890–3897. doi: 10.1182/blood-2006-04-017061. PubMed DOI PMC

Fialkow P., Najfeld V., Reddy A.L., Singer J., Steinmann L. Chronic lymphocytic leukæmia: Clonal origin in a committed b-lymphocyte progenitor. Lancet. 1978;312:444–446. doi: 10.1016/S0140-6736(78)91444-7. PubMed DOI

Hudecek M., Schmitt T.M., Baskar S., Lupo-Stanghellini M.T., Nishida T., Yamamoto T.N., Bleakley M., Turtle C.J., Chang W.-C., Greisman H.A., et al. The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010;116:4532–4541. doi: 10.1182/blood-2010-05-283309. PubMed DOI PMC

Berger C., Sommermeyer D., Hudecek M., Berger M., Balakrishnan A., Paszkiewicz P.J., Kosasih P.L., Rader C., Riddell S.R. Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells. Cancer Immunol. Res. 2015;3:206–216. doi: 10.1158/2326-6066.CIR-14-0163. PubMed DOI PMC

Scarfò I., Ormhøj M., Frigault M.J., Castano A.P., Lorrey S., Bouffard A.A., Van Scoyk A., Rodig S.J., Shay A.J., Aster J.C., et al. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood. 2018;132:1495–1506. doi: 10.1182/blood-2018-04-842708. PubMed DOI PMC

Faitschuk E., Hombach A.A., Frenzel L.P., Wendtner C.-M., Abken H. Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells. Blood. 2016;128:1711–1722. doi: 10.1182/blood-2016-01-692046. PubMed DOI

Rossi D., Sozzi E., Puma A., De Paoli L., Rasi S., Spina V., Gozzetti A., Tassi M., Cencini E., Raspadori D., et al. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br. J. Haematol. 2009;146:64–75. doi: 10.1111/j.1365-2141.2009.07711.x. PubMed DOI

Tinhofer I., Weiss L., Gassner F., Rubenzer G., Holler C., Greil R. Difference in the Relative Distribution of CD4+ T-cell Subsets in B-CLL With Mutated and Unmutated Immunoglobulin (Ig) VH Genes. J. Immunother. 2009;32:302–309. doi: 10.1097/CJI.0b013e318197b5e4. PubMed DOI

Görgün G., Holderried T.A.W., Zahrieh D., Neuberg D., Gribben J.G. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J. Clin. Investig. 2005;115:1797–1805. doi: 10.1172/JCI24176. PubMed DOI PMC

Ramsay A.G., Johnson A.J., Lee A.M., Görgün G., Le Dieu R., Blum W., Byrd J.C., Gribben J.G. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Investig. 2008;118:2427–2437. doi: 10.1172/JCI35017. PubMed DOI PMC

Palma M., Gentilcore G., Heimersson K., Mozaffari F., Näsman-Glaser B., Young E., Rosenquist R., Hansson L., Österborg A., Mellstedt H. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017;102:562–572. doi: 10.3324/haematol.2016.151100. PubMed DOI PMC

Riches J.C., Davies J.K., McClanahan F., Fatah R., Iqbal S., Agrawal S., Ramsay A.G., Gribben J.G. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121:1612–1621. doi: 10.1182/blood-2012-09-457531. PubMed DOI PMC

Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K., Sharman J.P., Wierda W., Zhao W., Heerema N.A., et al. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clin. Cancer Res. 2020;26:3918–3927. doi: 10.1158/1078-0432.CCR-19-2856. PubMed DOI PMC

Fraietta J.A., Nobles C.L., Sammons M.A., Lundh S., Carty S.A., Reich T.J., Cogdill A.P., Morrissette J.J.D., DeNizio J.E., Reddy S., et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nat. Cell Biol. 2018;558:307–312. doi: 10.1038/s41586-018-0178-z. PubMed DOI PMC

Nobles C.L., Sherrill-Mix S., Everett J.K., Reddy S., Fraietta J.A., Porter D.L., Frey N., Gill S.I., Grupp S.A., Maude S.L., et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J. Clin. Investig. 2019;130:673–685. doi: 10.1172/JCI130144. PubMed DOI PMC

Herman S.E.M., Niemann C.U., Farooqui M., Jones J., Mustafa R.Z., Lipsky A., Saba N.F., Martyr S., Soto S., Valdez J.C., et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: Correlative analyses from a phase II study. Leukemia. 2014;28:2188–2196. doi: 10.1038/leu.2014.122. PubMed DOI PMC

Mancikova V., Peschelova H., Kozlova V., Ledererova A., Ladungova A., Verner J., Loja T., Folber F., Mayer J., Pospisilova S., et al. Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. J. Immunother. Cancer. 2019;8:e000471. doi: 10.1136/jitc-2019-000471. PubMed DOI PMC

Xu X., Sun Q., Liang X., Chen Z., Zhang X., Zhou X., Li M., Tu H., Liu Y., Tu S., et al. Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. Front. Immunol. 2019;10:2664. doi: 10.3389/fimmu.2019.02664. PubMed DOI PMC

Shalabi H., Kraft I.L., Wang H.-W., Yuan C.M., Yates B., Delbrook C., Zimbelman J.D., Giller R., Stetler-Stevenson M., Jaffe E.S., et al. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica. 2018;103:e215–e218. doi: 10.3324/haematol.2017.183459. PubMed DOI PMC

Orlando E.J., Han X., Tribouley C., Wood P.A., Leary R.J., Riester M., Levine J.E., Qayed M., Grupp S.A., Boyer M., et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat. Med. 2018;24:1504–1506. doi: 10.1038/s41591-018-0146-z. PubMed DOI

Sotillo E., Barrett D.M., Black K.L., Bagashev A., Oldridge D.A., Wu G., Sussman R.T., LaNauze C., Ruella M., Gazzara M.R., et al. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015;5:1282–1295. doi: 10.1158/2159-8290.CD-15-1020. PubMed DOI PMC

Gardner R., Wu D., Cherian S., Fang M., Hanafi L.-A., Finney O., Smithers H., Jensen M.C., Riddell S.R., Maloney D.G., et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406–2410. doi: 10.1182/blood-2015-08-665547. PubMed DOI PMC

Jacoby E., Nguyen S.M., Fountaine T.J., Welp K., Gryder B., Qin H., Yang Y., Chien C.D., Seif A.E., Lei H., et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat. Commun. 2016;7:12320. doi: 10.1038/ncomms12320. PubMed DOI PMC

June C.H., O’Connor R.S., Kawalekar O.U., Ghassemi S., Milone M.C. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–1365. doi: 10.1126/science.aar6711. PubMed DOI

Teachey D.T., Lacey S.F., Shaw P.A., Melenhorst J.J., Maude S.L., Jeffrey F., Pequignot E., Gonzalez V.E., Chen F., Finklestein J., et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016;6:664–679. doi: 10.1158/2159-8290.CD-16-0040. PubMed DOI PMC

Gauthier J., Hirayama A.V., Hay M.K.A., Li D., Lymp J., Sheih A., Purushe J., Pender M.B.S., Hawkins B.R.M., Vakil M.A., et al. Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL. Blood. 2018;132:299. doi: 10.1182/blood-2018-99-111061. DOI

Lemal R., Tournilhac O. State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. J. Immunother. Cancer. 2019;7:202. doi: 10.1186/s40425-019-0686-x. PubMed DOI PMC

Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro